Assembly Biosciences Inc (ASMB)
| Sector • Healthcare Industry • Major Pharmaceutical Preparations |
| Industry • Major Pharmaceutical Preparations |
| Sector • Healthcare |
Looking into fourth quarter of 2021 effort, the company's made top-line remained unaltered
company delivered fourth quarter of 2021 operating deficit of $-62.889 million
Published 2022-03-16T03:20:39+00:00
Goran Soko / CSIMarket.com Contributer
![pills_blue_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg "pills_blue_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons")
For the October to December 31 2021 interval company increased a shortfall per share of $-1.34 per share compare to $-1.11 a year ago and advanced shortfall from $-0.41 per share from the preceding reporting season. The revenue remained unaffected to $0.00 million from $1.04 million in the same reporting season a year ago and sequentially from $6.25 million.
For the October to December 31 2021 interval Assembly Biosciences Inc realized net shortfall of $-60.257 million, higher than $-39.418 million a year ago.
Even more, the ASMB claimed also net deficit of $-93.09 million and for the financial year 2022, revenue of $0.00 million.
Major Pharmaceutical Preparations The Major Pharmaceutical Preparations company has decreased it's shortfall per share to $-1.92 from $-3.00 in the preceding fiscal year, while by 0 % from $6.25 million a year ago.
Assembly Biosciences Inc is expected to report next financial earnings on August 08, 2023.